CompletedPhase 1ACTRN12610000539033

The immediate effects of the hOrmone Urocortin on the nerve Control of blood pressure and Heart ratE.

The immediate effects of Urocortin 2 on Muscle Sympathetic Nerve Activity and haemodynamics in healthy men versus men with stable heart failure


Sponsor

Health Research Council of New Zealand

Enrollment

16 participants

Start Date

Oct 7, 2010

Study Type

Interventional

Conditions

Summary

Cardiovascular disease is a leading cause of death and significant burden on our health system. Existing drug treatments remain less than ideal. We need additional effective strategies for management of these patients. Reducing sympathetic nerve firing directed at the heart, which may exacerbate heart damage and cause sudden death, is desirable following heart attacks. A family of hormones, the urocortins (Ucn), have been proposed as novel therapeutic agents in this setting. We propose to determine whether Ucn can also inhibit sympathetic nerve activity (measured in the leg) in 8 healthy male volunteers and 8 males with stable heart failure. Participants will receive in a random order either Ucn2 (25 ug over 60 min) or matching placebo infusions on 2 separate occasions separated by 8 weeks. Each study day will occur on the fourth day of identical and constant salt controlled diets. On the morning of each study day, subjects will positioned in a lazy-boy reclined chair where they will remain for the duration of the study. Microneurography needles will be inserted in the right superficial peroneal nerve in the lower leg. Blood pressure will be measured continuously throughtout the infusion. Nerve activity recordings and blood sampling will occur at 5-15 minute intervals from 30 minutes prior to infusion for 2 hours These studies should clarify the true therapeutic potential of Ucn in cardiovascular disease.


Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 60 Yearss

Inclusion Criteria6

  • Absence of significant respiratory, liver or renal disease, or active malignancy.
  • No drugs affecting haemodynamics or sympathetic nerve activity
  • Part 2: Inclusion
  • Stable left ventricular dysfunction with left ventricular ejection fraction <40%
  • New York Heart Association (NYHA) class II or III symptoms
  • Absence of significant respiratory, liver or renal disease, or active malignancy.

Exclusion Criteria1

  • Inability to give informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

We propose to determine whether Urocortin 2 (Ucn2) can inhibit sympathetic nerve activity (measured in the leg) in 8 healthy male volunteers and 8 males with stable heart failure. Participants will

We propose to determine whether Urocortin 2 (Ucn2) can inhibit sympathetic nerve activity (measured in the leg) in 8 healthy male volunteers and 8 males with stable heart failure. Participants will receive in a random order either Ucn2 (25 ug ) or matching placebo infusions over 60minutes on 2 separate occasions separated by 8 weeks. Each study day will occur on the third day of identical and constant salt controlled diets (Sodium 120mmol/day, Potassium 100mmol/day for 2 days prior to the infusion on Day 3. On the morning of each study day, subjects will positioned in a lazy-boy reclined chair where they will remain for the duration of the study. Microneurography needles will be inserted in the right superficial peroneal nerve in the lower leg. Blood pressure and nerve activity recordings will be measured continuously and blood sampling will occur at 15 minute intervals from 30 minutes prior to infusion to 2 hours after.


Locations(1)

Christchurch, New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000539033